Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A peptide's perspective on antigen presentation to the immune system

Nature Chemical Biology volume 9, pages 769–775 (2013)Cite this article

Subjects

Abstract

Specific immune responses are critically dependent on protein degradation products in the form of peptides. These peptides are presented by major histocompatibility complexes (MHCs), and recognition of MHC–peptide complexes by the immune system determines successful pathogen elimination, transplant rejection, autoimmunity or death. Here we review the immune response from the peptide's perspective and discuss the fate of peptides in cells before presentation by MHC complexes. We then discuss how peptides are altered post-translationally to yield immune responses and how peptides can be engineered to achieve strong immune responses following vaccination. Although peptides are simple from a chemical perspective, they are complex in their immunological consequences.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The basics of peptide presentation by MHC molecules.
Figure 2: Peptides binding to MHC class I and II molecules.
Figure 3: Chemical alterations to alter MHC-peptide affinity and proteolytic stability.

References

  1. Reinherz, E.L. et al. The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286, 1913–1921 (1999).

    Article  CAS  PubMed  Google Scholar 

  2. Garcia, K.C. et al. An ab T cell receptor structure at 2.5 Å and its orientation in the TCR–MHC complex. Science 274, 209–219 (1996). The first MHC–TCR co-crystal showing how the TCR recognizes the combination of MHC class I and peptide.

    Article  CAS  PubMed  Google Scholar 

  3. Lo, W.L. & Allen, P.M. Self-peptides in TCR repertoire selection and peripheral T cell function. Curr. Top. Microbiol. Immunol. (2013).

  4. Neefjes, J., Jongsma, M.L., Paul, P. & Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11, 823–836 (2011).

    Article  CAS  PubMed  Google Scholar 

  5. Cho, J.H. & Gregersen, P.K. Genomics and the multifactorial nature of human autoimmune disease. N. Engl. J. Med. 365, 1612–1623 (2011).

    Article  CAS  PubMed  Google Scholar 

  6. Yewdell, J.W., Reits, E. & Neefjes, J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 3, 952–961 (2003).

    Article  CAS  PubMed  Google Scholar 

  7. Murata, S., Takahama, Y. & Tanaka, K. Thymoproteasome: probable role in generating positively selecting peptides. Curr. Opin. Immunol. 20, 192–196 (2008).

    Article  CAS  PubMed  Google Scholar 

  8. Nitta, T., Murata, S., Ueno, T., Tanaka, K. & Takahama, Y. Thymic microenvironments for T-cell repertoire formation. Adv. Immunol. 99, 59–94 (2008).

    Article  CAS  PubMed  Google Scholar 

  9. Kloetzel, P.M. & Ossendorp, F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 16, 76–81 (2004).

    Article  CAS  PubMed  Google Scholar 

  10. Cascio, P., Hilton, C., Kisselev, A.F., Rock, K.L. & Goldberg, A.L. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J. 20, 2357–2366 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Reits, E. et al. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20, 495–506 (2004).

    Article  CAS  PubMed  Google Scholar 

  12. Reits, E. et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 18, 97–108 (2003). This study shows the fate of peptides in living cells using 'single-cell biochemistry'. It also shows that peptides live for few seconds in living cells unless they are N-terminally protected from aminopeptidases.

    Article  CAS  PubMed  Google Scholar 

  13. Neefjes, J.J., Momburg, F. & Hammerling, G.J. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 261, 769–771 (1993).

    Article  CAS  PubMed  Google Scholar 

  14. Momburg, F., Roelse, J., Hammerling, G.J. & Neefjes, J.J. Peptide size selection by the major histocompatibility complex-encoded peptide transporter. J. Exp. Med. 179, 1613–1623 (1994).

    Article  CAS  PubMed  Google Scholar 

  15. Chang, S.C., Momburg, F., Bhutani, N. & Goldberg, A.L. The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a “molecular ruler” mechanism. Proc. Natl. Acad. Sci. USA 102, 17107–17112 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ortmann, B. et al. A critical role for tapasin in the assembly and function of multimeric MHC class I–TAP complexes. Science 277, 1306–1309 (1997).

    Article  CAS  PubMed  Google Scholar 

  17. Roelse, J., Gromme, M., Momburg, F., Hammerling, G. & Neefjes, J. Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J. Exp. Med. 180, 1591–1597 (1994).

    Article  CAS  PubMed  Google Scholar 

  18. Romagnoli, P. & Germain, R.N. The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J. Exp. Med. 180, 1107–1113 (1994).

    Article  CAS  PubMed  Google Scholar 

  19. Ghosh, P., Amaya, M., Mellins, E. & Wiley, D.C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378, 457–462 (1995).

    Article  CAS  PubMed  Google Scholar 

  20. Pos, W. et al. Crystal structure of the HLA-DM–HLA-DR1 complex defines mechanisms for rapid peptide selection. Cell 151, 1557–1568 (2012). A crystal structure of a designed HLA-DR1 dimer with HLA-DM revealing how a chaperone manipulates the HLA-DR1 structure to allow peptide binding.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Denzin, L.K. & Cresswell, P. HLA-DM induces CLIP dissociation from MHC class II ab dimers and facilitates peptide loading. Cell 82, 155–165 (1995).

    Article  CAS  PubMed  Google Scholar 

  22. Roche, P.A. & Cresswell, P. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc. Natl. Acad. Sci. USA. 1991. 88: 3150–3154. J. Immunol. 187, 1076–1080 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Stanfield, R.L. & Wilson, I.A. Protein-peptide interactions. Curr. Opin. Struct. Biol. 5, 103–113 (1995).

    Article  CAS  PubMed  Google Scholar 

  24. Spee, P. & Neefjes, J. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur. J. Immunol. 27, 2441–2449 (1997).

    Article  CAS  PubMed  Google Scholar 

  25. Lammert, E., Stevanovic, S., Brunner, J., Rammensee, H.G. & Schild, H. Protein disulfide isomerase is the dominant acceptor for peptides translocated into the endoplasmic reticulum. Eur. J. Immunol. 27, 1685–1690 (1997).

    Article  CAS  PubMed  Google Scholar 

  26. Matsumura, M., Fremont, D.H., Peterson, P.A. & Wilson, I.A. Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science 257, 927–934 (1992).

    Article  CAS  PubMed  Google Scholar 

  27. Speir, J.A., Stevens, J., Joly, E., Butcher, G.W. & Wilson, I.A. Two different, highly exposed, bulged structures for an unusually long peptide bound to rat MHC class I RT1-Aa. Immunity 14, 81–92 (2001).

    Article  CAS  PubMed  Google Scholar 

  28. Stern, L.J. et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368, 215–221 (1994).

    Article  CAS  PubMed  Google Scholar 

  29. Mohan, J.F. & Unanue, E.R. A novel pathway of presentation by class II-MHC molecules involving peptides or denatured proteins important in autoimmunity. Mol. Immunol. 55, 166–168 (2013).

    Article  CAS  PubMed  Google Scholar 

  30. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G. & Rammensee, H.G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290–296 (1991). Breakthrough paper describing conserved amino acids within the peptide set associated to a particular MHC class I molecule. These so-called anchor residues appeared to fill pockets in the MHC class I (and class II) structure.

    Article  CAS  PubMed  Google Scholar 

  31. Madden, D.R., Garboczi, D.N. & Wiley, D.C. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 75, 693–708 (1993).

    Article  CAS  PubMed  Google Scholar 

  32. Hanada, K., Yewdell, J.W. & Yang, J.C. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427, 252–256 (2004). This study shows the concept of peptide splicing yielding new peptides for MHC class I antigen presentation. These peptides are not genetically encoded but are the result of proteasomal degradation and proteasomal ligation into a new combination to result post-translationally in a new peptide sequence.

    Article  CAS  PubMed  Google Scholar 

  33. Vigneron, N. et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 304, 587–590 (2004). This study shows the concept of peptide splicing yielding new peptides for MHC class I antigen presentation. These peptides are not genetically encoded but are the result of proteasomal degradation and proteasomal ligation into a new combination to result post-translationally in a new peptide sequence.

    Article  CAS  PubMed  Google Scholar 

  34. Warren, E.H. et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 313, 1444–1447 (2006).

    Article  CAS  PubMed  Google Scholar 

  35. Grommé, M. et al. The rational design of TAP inhibitors using peptide substrate modifications and peptidomimetics. Eur. J. Immunol. 27, 898–904 (1997).

    Article  PubMed  Google Scholar 

  36. Andersen, M.H. et al. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J. Immunol. 163, 3812–3818 (1999).

    CAS  PubMed  Google Scholar 

  37. Haurum, J.S. et al. Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J. Exp. Med. 190, 145–150 (1999).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Altrich-VanLith, M.L. et al. Processing of a class I–restricted epitope from tyrosinase requires peptide N-glycanase and the cooperative action of endoplasmic reticulum aminopeptidase 1 and cytosolic proteases. J. Immunol. 177, 5440–5450 (2006).

    Article  CAS  PubMed  Google Scholar 

  39. Wang, Y. & Dai, S. Structural basis of metal hypersensitivity. Immunol. Res. 55, 83–90 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Illing, P.T. et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486, 554–558 (2012). This is the first study showing how particular drugs can bind in the MHC class I peptide-binding groove to alter the conformation of peptides and thus the immune response.

    Article  CAS  PubMed  Google Scholar 

  41. Romagnoli, P., Labhardt, A.M. & Sinigaglia, F. Selective interaction of Ni with an MHC-bound peptide. EMBO J. 10, 1303–1306 (1991).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Falta, M.T. et al. Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease. J. Exp. Med. 1403–1418. (2013).

  43. Sollid, L.M., Qiao, S.W., Anderson, R.P., Gianfrani, C. & Koning, F. Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics 64, 455–460 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  44. Wucherpfennig, K.W. & Hafler, D.A. A review of T-cell receptors in multiple sclerosis: clonal expansion and persistence of human T-cells specific for an immunodominant myelin basic protein peptide. Ann. NY Acad. Sci. 756, 241–258 (1995).

    Article  CAS  PubMed  Google Scholar 

  45. Mallone, R., Brezar, V. & Boitard, C. T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives. Clin. Dev. Immunol. 2011, 513210 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Thomson, G. et al. Genetic heterogeneity, modes of inheritance, and risk estimates for a joint study of Caucasians with insulin-dependent diabetes mellitus. Am. J. Hum. Genet. 43, 799–816 (1988).

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Stritesky, G.L., Jameson, S.C. & Hogquist, K.A. Selection of self-reactive T cells in the thymus. Annu. Rev. Immunol. 30, 95–114 (2012).

    Article  CAS  PubMed  Google Scholar 

  48. Lyons, D. S. et al. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 5, 53–61 (1996).

    Article  CAS  PubMed  Google Scholar 

  49. Larché, M. & Wraith, D.C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 11, S69–S76 (2005).

    Article  CAS  PubMed  Google Scholar 

  50. Kenter, G.G. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838–1847 (2009). This proof-of-principle study may be a basis for new vaccination strategies.

    Article  CAS  PubMed  Google Scholar 

  51. Paulis, L.E., Mandal, S., Kreutz, M. & Figdor, C.G. Dendritic cell-based nanovaccines for cancer immunotherapy. Curr. Opin. Immunol. 25, 389–395 (2013).

    Article  CAS  PubMed  Google Scholar 

  52. Kast, W.M. et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. USA 88, 2283–2287 (1991).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. DeNardo, S.J. et al. Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. Clin. Cancer Res. 9, 3854S–3864S (2003).

    CAS  PubMed  Google Scholar 

  54. Bontrop, R.E. Comparative genetics of MHC polymorphisms in different primate species: duplications and deletions. Hum. Immunol. 67, 388–397 (2006).

    Article  CAS  PubMed  Google Scholar 

  55. Strominger, J.L. & Wiley, D.C. The 1995 Albert Lasker Medical Research Award. The class I and class II proteins of the human major histocompatibility complex. J. Am. Med. Assoc. 274, 1074–1076 (1995).

    Article  CAS  Google Scholar 

  56. Pircher, H. et al. Viral escape by selection of cytotoxic T cell–resistant virus variants in vivo. Nature 346, 629–633 (1990).

    Article  CAS  PubMed  Google Scholar 

  57. Jorritsma, A., Schumacher, T.N. & Haanen, J.B. Immunotherapeutic strategies: the melanoma example. Immunotherapy 1, 679–690 (2009).

    CAS  PubMed  Google Scholar 

  58. Khan, S. et al. Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. Mol. Immunol. 46, 1084–1091 (2009). An example of designed modification of synthetic peptides with TLR ligands to further improve vaccination. These strategies may be coupled to long peptides for successful vaccines.

    Article  CAS  PubMed  Google Scholar 

  59. Khan, S. et al. Distinct uptake mechanisms but similar intracellular processing of two different Toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem. 282, 21145–21159 (2007).

    Article  CAS  PubMed  Google Scholar 

  60. Neefjes, J.J., Smit, L., Gehrmann, M. & Ploegh, H.L. The fate of the three subunits of major histocompatibility complex class I molecules. Eur. J. Immunol. 22, 1609–1614 (1992).

    Article  CAS  PubMed  Google Scholar 

  61. Engels, B. et al. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 23, 516–526 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Valeur, E. & Bradley, M. Amide bond formation: beyond the myth of coupling reagents. Chem. Soc. Rev. 38, 606–631 (2009).

    Article  CAS  PubMed  Google Scholar 

  63. El-Faham, A. & Albericio, F. Peptide coupling reagents, more than a letter soup. Chem. Rev. 111, 6557–6602 (2011).

    Article  CAS  PubMed  Google Scholar 

  64. Kammertoens, T. & Blankenstein, T. It's the peptide-MHC affinity, stupid. Cancer Cell 23, 429–431 (2013).

    Article  CAS  PubMed  Google Scholar 

  65. Townsend, A.R. et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44, 959–968 (1986). This is the first paper showing that peptides rather than proteins from a virus were detected by cytotoxic T cells. This paper was first received with skepticism in the field.

    Article  CAS  PubMed  Google Scholar 

  66. Fremont, D.H., Matsumura, M., Stura, E.A., Peterson, P.A. & Wilson, I.A. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science 257, 919–927 (1992).

    Article  CAS  PubMed  Google Scholar 

  67. Andersson, I.E., Dzhambazov, B., Holmdahl, R., Linusson, A. & Kihlberg, J. Probing molecular interactions within class II MHC Aq/glycopeptide/T-cell receptor complexes associated with collagen-induced arthritis. J. Med. Chem. 50, 5627–5643 (2007).

    Article  CAS  PubMed  Google Scholar 

  68. Reinelt, S. et al. β-amino acid scan of a class I major histocompatibility complex-restricted alloreactive T-cell epitope. J. Biol. Chem. 276, 24525–24530 (2001).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by a Horizon grant from the Netherlands Genomics Initiative to H.O., a European Research Council advanced grant to J.N. and a Netherlands Organisation for Scientific Research–Chemische Wetenschappen (NWO-CW) TOP grant jointly to H.O. and J.N. We thank P. Celie and M. Garstka for help with figures.

Author information

Authors and Affiliations

  1. Division of Cell Biology, the Netherlands Cancer Institute, Amsterdam, The Netherlands

    Jacques Neefjes & Huib Ovaa

Authors
  1. Jacques Neefjes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huib Ovaa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jacques Neefjes or Huib Ovaa.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Neefjes, J., Ovaa, H. A peptide's perspective on antigen presentation to the immune system. Nat Chem Biol 9, 769–775 (2013). https://doi.org/10.1038/nchembio.1391

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nchembio.1391

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing